The PD-L1 antibody atezolizumab showed poor response in the predominant microsatellite stable form of CRC as a monotherapy, but improved overall response rates in combination with an MEK inhibitor or α-VEGF and standard folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX) chemotherapy15. Here, CD274 is linked to colorectal carcinoma.